Cellares Partners with Sonoma Biotherapeutics to Automate Treg Cell Therapy Manufacturing — Cellares Corporation

Event summary

Cellares and Sonoma Biotherapeutics collaborate to automate manufacturing of SBT-77-7101, an autologous CAR-Treg cell therapy for poly-refractory rheumatoid arthritis.
SBT-77-7101 is the first Treg cell therapy onboarded to Cellares' Cell Shuttle platform, extending its capabilities into a modality requiring precise handling and analytical control.
Cellares will automate in-process and release testing through its Cell Q quality control system, addressing the labor-intensive and sensitive nature of Treg manufacturing.
Sonoma Biotherapeutics is collaborating with Regeneron to advance a pipeline of Treg cell therapies for autoimmune diseases.

The big picture

This partnership underscores the growing trend of automating complex cell therapy manufacturing processes to improve scalability and cost-efficiency. As Treg therapies gain traction for treating autoimmune diseases, Cellares' platform could become a critical enabler for bringing these treatments to market. The collaboration also highlights the strategic importance of global manufacturing infrastructure in supporting late-stage clinical trials and commercialization.

What we're watching

Technical Validation: Whether Cellares can successfully translate SonomaBio’s proprietary manufacturing process onto the Cell Shuttle platform and maintain Treg identity and function.
Scale and Economics: The pace at which Cellares can deliver the economics and throughput needed to advance SBT-77-7101 toward late-stage clinical trials and commercial readiness.
Market Expansion: How this collaboration will position Cellares in the Treg cell therapy market, particularly as it expands its global manufacturing network.